
NICE and Flatiron partner to utilise real-world oncology data in informing decisions about cancer therapy access
10 August 2022
- Flatiron Health are already partnered with the FDA in the US since 2016, with whom they have explored real-world outcomes and alternative study methods
- Experts from both NICE and Flatiron Health will conduct research using Flatiron’s electronic health record (EHR)-derived database
- “We are excited to explore how real-world evidence could be incorporated into our work in the future. Working in this way will test how additional sources of evidence could complement trial and research data in our technology appraisals, especially in helping to resolve uncertainty in the evidence.” – Pall Jonsson, Associate Director for Science Policy and Research, NICE